Clinical Trial ResultsThe trial achieved its primary endpoint of progression-free survival, with marked improvements across key secondary endpoints.
Drug DevelopmentIncyte presented early data for its potential first-in-class CDK2 inhibitor, which demonstrated encouraging signs of clinical activity in patients with solid tumors, most notably those with ovarian cancer.
Standard Of Care PotentialData supports retifanlimab in combination with carboplatin and paclitaxel could be a new standard of care in squamous cell anal carcinoma.